Randomized controlled trials of COX-2 inhibitors: An analysis of doses used and trends over time to investigate implications for comparative safety

Drug Safety

Volumn 34, Issue 9, 2011, Pages 783-792

  Stefansdottir, Gudrun ^a,b   De Bruin, Marie L ^a,b,c   Knol, Mirjam J ^a,b   Grobbee, Diederick E ^a   Leufkens, Hubert G M ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Adverse reaction monitoring; Celecoxib; Clinical trial design; Cyclo oxygenase 2 inhibitors; Diclofenac; Ibuprofen; Naproxen; Nonsteroidal anti inflammatories; Rofecoxib

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ANALGESIA; ARTICLE; CARDIOVASCULAR RISK; COCHRANE LIBRARY; COMPARATIVE STUDY; CONTROLLED STUDY; DEFINED DAILY DOSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; PAIN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREND STUDY;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 80051587187     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11590470-000000000-00000     Document Type: Article

References (33)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343 (21): 1520-8
2. Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003; 139 (7): 539-46
3. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372 (9651): 1756-64
4. Merck. Merck announces voluntary worldwide withdrawal of Vioxx [news release; online]. Available from URL: http://www.merck.com/newsroom/vioxx/pdf/ vioxx-press-release-final.pdf [Accessed 2011 May 12]
5. EMEA. Public CHMP assessment report for medicinal products containing non-selective non-steroidal anti-inflammatory drugs (NSAIDs) [EMEA/CHMP/442130/2006]. London: European Medicines Agency, 2006
6. US FDA. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyIn formationforPatientsandProviders/UCM103420 [Accessed 2011 May 12]
7. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 2002; 39 (3): 521-2 (Pubitemid 34117511)
8. Bueno H, Bardaji A, Patrignani P, et al. Use of nonsteroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010; 105 (8): 1102-6
9. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98 (3): 266-74
10. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27 (14): 1657-63 (Pubitemid 44025350)
11. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49 (3): 408-18
12. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115 (12): 1634-42 (Pubitemid 46648649)
13. Frankish H. Why do COX-2 inhibitors increase risk of cardiovascular events [letter]? Lancet 2002; 359 (9315): 1410
14. Fitzgerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002; 89 (6A): 26-32D
15. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996; 271 (52): 33157-60
16. FDA. COX-2 selective (includes Bextra, Celebrex and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Silver Spring (MD): Food and Drug Administration, 2005
17. EMEA. European Medicines Agency concludes action on COX-2 inhibitors (EMEA/207766/2005). London: European Medicines Agency, 2005
18. Solomon SD, McMurray JJ, PfefferMA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352 (11): 1071-80 (Pubitemid 40365348)
19. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355 (9): 885-95 (Pubitemid 44315981)
20. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117 (16): 2104-13 (Pubitemid 351572169)
21. WHO. About the ATC/DDD system [online]. Available from URL: http://www.whocc.no/atcddd/atcsystem.html [Accessed 2009 May 18]
22. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40 (2): 124-32
23. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA 2006; 296 (13): 1633-44 (Pubitemid 44511610)
24. Howes LG. Selective COX-2 inhibitors, NSAIDs and cardiovascular events-is celecoxib the safest choicé Ther Clin Risk Manag 2007; 3 (5): 831-45 (Pubitemid 350162082)
25. Scott PA, Kingsley GH, Scott DL. Non-steroidal antiinflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 2008; 10 (11): 1102-7
26. Arellano FM, Yood MU, Wentworth CE, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription nonsteroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations: implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006; 15 (12): 861-72 (Pubitemid 44941639)
27. Schnitzer TJ,Kong SX,Mitchell JH, et al. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther 2003; 25 (12): 3162-72
28. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109 (17): 2068-73 (Pubitemid 38620213)
29. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365 (9458): 475-81 (Pubitemid 40215729)
30. Lee YH, Ji JD, Song GG. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatol Int 2007; 27 (5): 477-82 (Pubitemid 46294989)
31. Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 2006; 67 (6): 897-903 (Pubitemid 44049088)
32. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52 (20): 1628-36
33. Ross JS, Madigan D, Hill KP, et al. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009; 169 (21): 1976-85